BioWorld MedTech

June 14, 2010

Sicel touts dose device at radiotherapeutics meeting

Undergoing radiation therapy is often the best chance a patient has at getting rid of a tumor, but the treatment sometimes comes with an unfortunate – even fatal – price if the patient receives too much. (Medical Device Daily) Read More

AAPM; clinics responsible for QA, but industry must pitch in

Financings roundup: SonoSite to repurchase up to $50M of its common stock

Checkpoint's neurostimulation device launched nationwide

International report: SFDA clears China Medical Technologies' HPV-DNA chip

MDD's food for med-tech thought

Deals roundup: Orthopaedic Synergy wraps up Praxim acquisition

Agreements/contracts: TransEnterix selects Syspro ERP software for real-time data

Court Report: U.S. wins $2.75 million in Medicaid fraud settlement

Product Briefs

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...